The project is building on a 2020 research study, conducted during the COVID-19 pandemic, that identified strategic opportunities to improve health and wellbeing for tens of millions of people while reducing US spending on likely-avoidable hospitalizations, emergency department and doctor visits by as much as $528 billion dollars. The University of Colorado Skaggs School of Pharmacy will contribute to this effort by supporting research and action in areas including state-level strategies for Colorado and special study sections including practice/payment model transformation and health access and equity.
Duke-NUS, Xylonix join forces to improve effectiveness of Xylonix cancer drugs. New drug formulations aim to improve the in vivo circulation of Xylonix’s novel immunotherapies for treating both cancer and complications arising from COVID-19 infection.
- Singapore’s Health and Biomedical Sciences (HBMS) Industry Alignment Fund Pre-Positioning (IAF-PP) grant
The Innovative Medicines Initiative (IMI) announced the launch of OPTIMA (Optimal Treatment for Patients with Solid Tumours in Europe Through Artificial intelligence), a € 21.3 million public-private research programme that will seek to use artificial intelligence (AI) to improve care for patients with prostate, breast and lung cancer.
The Lehigh University College of Health is pleased to announce the creation of the Institute of Health Policy and Politics (IHPP).
SWOG Cancer Research Network and its charitable arm, The Hope Foundation for Cancer Research, have jointly developed a website for SWOG Clinical Trials Partnerships (SWOG CTP) as a public resource for current and potential partners to learn about SWOG CTP's structure and staff, how it conducts research, its latest news, and how to get involved.
The German Research Center for Geosciences (GFZ) has set up a task force and sent a team to La Palma to contribute to the rapid assessment of volcanic eruptions and earthquakes on the islands. Together with experts in Potsdam and Spain, the researchers are investigating the interaction of the eruption with the quakes and surface deformations. They are using on-site measuring instruments and satellite images as well as data and software from the worldwide earthquake measuring network GEOFON.
The White House today issued a proclamation that restores the boundaries of two US national monuments in Utah that are closely linked to paleontological science, Grand Staircase-Escalante and Bears Ears.
The SingHealth Duke-NUS Maternal and Child Health Research Institute (MCHRI) was launched at KK Women’s and Children’s Hospital (KKH) today by Masagos Zulkifli, Singapore’s Minister for Social and Family Development and Second Minister for Health. The MCHRI will serve as the centre of excellence for maternal and child health research, to transform and improve national health in Singapore. Its mission is to support the growth and development of every woman and child to their fullest potential, toward optimising Singapore’s human capital.
The Social and Interactive Learning at Community Colleges (SAIL-CC) program will be piloted at colleges representing a variety of geographic locations, rural and urban settings, school sizes, faculty and student demographics, required learning objectives, and other factors. SAIL-CC will design and develop innovative methods and tools to improve teaching and learning in entry-level information technology and computer science courses taught at community colleges. TEEL Lab educational researchers will lead the project, working closely with NISOD and instructors from five community colleges across the U.S. The SAIL-CC grant has been funded as a Level III Engaged Student Learning Project through the National Science Foundation's Improving Undergraduate STEM Education Initiative.
The investigational Alzheimer’s drug CMS121, developed and studied at Salk over the last fifteen years, has now moved into a phase I clinical trial to evaluate its safety in humans. Salk Research Professor Pamela Maher and Bill Raschke of Virogenics, Inc. will receive $4.5 million over two years from the National Institute of Aging to support the trial, and they expect the first doses to be administered to healthy volunteers in early 2022. In mice, CMS121 reverses signs of aging in the brain and prevents the memory loss associated with Alzheimer’s disease.
RTOG Foundation and NSABP Foundation, two of the three entities that initially collaborated to establish NRG Oncology, recently announced their financial support of the NRG Oncology Health Equity New Investigator Mentor Program for Underrepresented Minority Scholars.